Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies. The biopharma has ...

Blueprint is accelerating the development of its CDK2 and CDK4 targeted protein degraders, focusing on their potential to achieve best-in-class profiles for treating breast cancer and other solid ...

Blueprint is advancing CDK2 and CDK4 targeted protein degraders, which have progressed faster than expected in preclinical development toward potentially best-in-class profiles and is prioritizing ...

In addition, Monte Rosa is positioned to advance its third clinical candidate, MRT-8102, into clinical development later this year, and we also expect to nominate development candidates for our CDK2 ...

Blueprint is advancing CDK2 and CDK4 targeted protein degraders, which have progressed faster than expected in preclinical development toward potentially best-in-class profiles and is prioritizing ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Nintendo tends to introduce wholly new consoles that build on the features and power of ...

Your W-2 form, or Wage and Tax Statement, helps you to fill out your annual tax return. Here's more on how to understand the form and what to do if it’s wrong. Many, or all, of the products ...

-- Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates -- -- Expect to achieve ...

Oli Welsh is senior editor, U.K., providing news, analysis, and criticism of film, TV, and games. He has been covering the business & culture of video games for two decades. After many months, if ...